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AEBP1 down regulation induced 
cell death pathway depends on 
PTEN status of glioma cells
Swati Sinha1, Arun Renganathan1,2, Prathima B. Nagendra1,3, Vasudeva Bhat  1,4, 
Brian Steve Mathew1 & Manchanahalli R. Satyanarayana Rao1
Glioblastoma (GBM) is the most common aggressive form of brain cancer with overall dismal prognosis 
(10–12 months) despite all current multimodal treatments. Previously we identified adipocyte enhancer 
binding protein 1 (AEBP1) as a differentially regulated gene in GBM. On probing the role of AEBP1 over 
expression in glioblastoma, we found that both cellular proliferation and survival were affected upon 
AEBP1 silencing in glioma cells, resulting in cell death. In the present study we report that the classical 
caspase pathway components are not activated in cell death induced by AEBP1 down regulation in 
PTEN-deficient (U87MG and U138MG) cells. PARP-1 was not cleaved but over-activated under AEBP1 
down regulation which leads to the synthesis of PAR in the nucleus triggering the release of AIF from the 
mitochondria. Subsequently, AIF translocates to the nucleus along with MIF causing chromatinolysis. 
AEBP1 positively regulates PI3KinaseCβ by the binding to AE-1 binding element in the PI3KinaseCβ 
promoter. Loss of PI3KinaseCβ expression under AEBP1 depleted condition leads to excessive DNA 
damage and activation of PARP-1. Furthermore, over expression of PIK3CB (in trans) in U138MG 
cells prevents DNA damage in these AEBP1 depleted cells. On the contrary, AEBP1 down regulation 
induces caspase-dependent cell death in PTEN-proficient (LN18 and LN229) cells. Ectopic expression of 
wild-type PTEN in PTEN-deficient U138MG cells results in the activation of canonical caspase and Akt 
dependent cell death. Collectively, our findings define AEBP1 as a potential oncogenic driver in glioma, 
with potential implications for therapeutic intervention.
Glioblastoma multiforme (GBM) is a very aggressive form of brain cancer with very poor prognosis. These can-
cer patients have overall survival span averaging one-year despite of multimodality therapeutic interventions 
involving surgery, radiotherapy with concomitant adjuvant chemotherapy. A better understanding of the genetic 
and the epigenetic determinants of GBM are being pursued actively for identifying novel effective therapeutic 
targets to treat these aggressive tumor cells. We had observed earlier that adipocyte enhancer binding protein 1 
(AEBP1) expression to be up-regulated in primary GBMs as opposed to progressive secondary GBMs through 
transcriptome analysis1. AEBP1 was originally discovered as a transcriptional repressor that binds to the AE-1 
element of the ap-2 gene which codes for the fatty acid binding protein 4 (FABP4)2. Fabp4 is involved in the differ-
entiation of preadipocytes to mature adipocytes and smooth muscle cell differentiation3. In addition to its role in 
the adipose tissue, AEBP1 is being increasingly implicated in different cancers. AEBP1 expression is up-regulated 
in prostate cancer4 and its up-regulation confers acquired resistance to BRAF (V600E) inhibition in melanoma5. 
AEBP1 is also reported to promote mammary cell hyperplasia through up-regulation of Hedgehog and NFkB 
pathway components6. A group of 10 genes including AEBP1 is linked to high metastasis and poor prognosis 
in serous ovarian cancer7. In an initial effort to understand the role of AEBP1 in primary glioma, we performed 
global gene expression profiling in AEBP1 down regulated U87MG glioma cell line and identified a large number 
of perturbed genes belonging to categories of cell cycle, differentiation, proliferation and apoptosis8. We also 
showed that down regulation of AEBP1 resulted in cell death of both U87MG and U138MG cells suggesting that 
AEBP1 may play an essential role as an oncogenic protein. This assumes great importance considering the fact 
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that migrating GBM cells are resistant to conventional apoptosis (Type I programmed cell death) due to the over 
expression of IAPs9, and therefore to radiotherapy and conventional chemotherapy10, as a consequence of which 
GBM (Grade IV) patients have a poor prognosis with a median survival of only14.6 months11.
The conventional mechanisms of cell death are apoptosis, autophagy, and necroptosis. Although apop-
tosis is generally characterized by nuclear pyknosis, chromatin condensation, and phosphatidyl serine expo-
sure on the plasma membrane, these are not truly specific biomarkers for caspase activation. In an alternative, 
caspase-independent pathway, phylogenetically conserved death effector molecule termed AIF has been shown 
to mediate chromatin condensation and induce phosphatidyl serine exposure when caspase activation is inhib-
ited12,13. In some paradigms of yeast cell death14 and in mammalian neurons15, AIF is necessary for cell death 
induction. AIF is typically confined to mitochondria but translocates to the nucleus under the influence of poly 
(ADP-ribose) (PAR) polymerase-1 (PARP-1) activation when cell death is induced16,17. This distinct cell death 
pathway mediated by events such as over activation of PARP1, PAR synthesis, nuclear AIF translocation and large 
scale DNA fragmentation are specific to the phenomenon of parthanatos18,19. This unique parthanatos distin-
guishes itself from caspase dependent apoptosis pathway in not involving relevant caspases. Our previous study 
shows that down regulation of AEBP1 in glioma cells resulted in cell death8, thus we were interested in exploring 
the actual mechanism of cell death triggered by depletion of AEBP1. In the present study, we deciphered that 
AEBP1 depletion-induced cell death mechanism in glioma cells and its dependence on the genetic background of 
tumor cells. We demonstrate that AEBP1 down regulation in Phosphatase and tensin homolog (PTEN)-deficient 
(U87MG and U138MG) cells causes phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta 
(PIK3CB) depletion by directly decreasing its transcript levels leading to large-scale DNA damage, hyperactiva-
tion of PARP-1, PAR polymer mediated release of AIF from mitochondria and subsequent caspase-independent 
cell death by Parthanatos20. On the other hand, AEBP1 down regulation in PTEN-proficient (LN18 and LN229) 
cells induces the classical caspase-dependent cell death pathway. It has been previously established that the lipid 
kinase activity of PI3KCβ is essential to maintain PI3Kinase signaling in PTEN deficient cells. Also PI3Kinase is 
essential for the maintenance of genomic integrity21. Furthermore, ectopic expression of PTEN wild-type cDNA 
in U138MG cells (PTEN deficient) induced caspase-dependent cell death pathway in AEBP1 depleted cells. Thus, 
PI3kinaseβ assumes importance in PTEN deficient tumors like glioma as its ablation impedes tumorigenesis. This 
is the first report of a transcription factor (AEBP1) acting as a potential oncogenic protein in GBM by regulating 
the expression of PI3KCB, which is increasingly being recognized as an important molecule in the pathobiology 
of many cancers22.
Materials and Methods
Cell culture and reagents. Glioma cells, U87MG, U138MG, LN18 and LN229 were purchased from ATCC 
and cultured in DMEM (Sigma Aldrich) supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin 
(Gibco) at 37 °C with 5% CO2. All fine chemicals were purchased from Sigma Aldrich and Life Technologies 
unless otherwise specified.
AEBP1 silencing. For down regulation of AEBP1 with small interfering RNAs (siRNA), GBM cells were 
transfected with 100 nM of siRNA pool (Supplementary Table S2, Dharmacon Inc.,USA) targeted against AEBP1 
or non-targeting scrambled siRNA pool by using Lipofectamine 2000 (Life technologies, USA). In our earlier 
study we observed no significant loss of cell viability in U138MG and U87MG cells during the first 4 days of post 
transfection even though AEBP1 was significantly down regulated at this time period. Furthermore, the reduction 
in cell viability was observed from 5th day onwards which suggested us that silencing of AEBP1 resulted in the loss 
of proliferative potential or cell death8. Nevertheless, we assessed the effect of AEBP1 silencing in U138MG cells 
on selected on-target (CAMTA1, MDM2, UBE3A, ARNT, CD93 and MAPK13) and off target genes (TP53INP1, 
DMTF1, ERBB2P and SIVA1) expression levels. These genes were categorized as on-target and off-target genes 
with respect to the presence of AE 1 binding element in their promoters8. As shown in the Supplementary Fig. 1 
AEBP1 silencing in U138MG does perturb its on-target genes but not its off-target genes. Thus, in this study 
siRNA pool was replenished every 60 hours in case of U87MG, LN18 and LN299 cells and every 36 hours in the 
case of U138MG cell line for over a period of 9 days to maintain the Aebp1 depleted condition. Total RNA was 
extracted using Trizol reagent and reverse transcription was carried out with RevertAid first strand cDNA syn-
thesis kit (Thermo Scientific, USA) according to the manufacturer’s protocol.
Antibodies. Antibodies used in this study are as follows: rabbit monoclonal anti-cleaved caspase 8 antibody 
(Novus Biologicals), rabbit monoclonal anti-cleaved caspase 9 antibody (Novus Biologicals), rabbit monoclonal 
anti-cleaved caspase 3 antibody (Novus Biologicals), rabbit polyclonal anti-cleaved PARP-1 antibody (Abcam), 
rabbit polyclonal anti-Bid cleavage site antibody (Abcam), rabbit monoclonal anti-AIF antibody (Abcam), mouse 
monoclonal anti-PAR antibody (Abcam), mouse monoclonal anti-MIF antibody (Cusabio), rabbit monoclonal 
anti-PI3Kinase p110 beta antibody (Abcam), mouse monoclonal anti-γH2AX antibody (raised in house) and 
rabbit polyclonal anti-GAPDH antibody (Abcam).
Western blot analysis. Proteins were separated by 10–15% SDS-PAGE, transferred to nitrocellulose mem-
branes (Amersham Bioscience), blocked with 5% skimmed milk/PBST, and then probed with antibodies as 
indicated. Protein bands were detected by chemiluminescence with the ECL system (Pierce) according to the 
manufacture’s protocol.
Luciferase reporter assay for promoter activity of PI3kinase catalytic sub unit beta. PI3kinase 
110 CB promoter (−2000–+200 bp) was amplified from genomic DNA isolated from U138MG glioma cells and 
cloned into the XhoI and HindIII sites of the basic pGL3-promoter vector (Promega Corp. USA). 2.5 × 104 cells 
were seeded per well in a 24-well plate, 24 hours prior to transfection. 2 μg of various reporter constructs were 
3Scientific RepoRtS |         (2019) 9:14577  | https://doi.org/10.1038/s41598-019-51068-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
co-transfected in U138MG and HeLa cells along with 200 ng of pCMVβ, (internal control plasmid pGL3-β Gal 
that expresses the β-galactosidase gene under the control of CMV promoter) as a transfection control. After 
24 hours of post transfection, cells were subjected to AEBP1 silencing for different time periods. Cells were pro-
cessed as prescribed in Pierce Firefly Luciferase Glow Assay Kit protocol (Thermoscientific USA) and relative 
light units were measured in a Luminometer (Berthold detection systems). β-galactosidase activity was measured 
by fluorometric assay and used to normalize transfection efficiency. The primers used in the study are listed in 
Supplementary Table 2.
Caspase-Glo 3/7 assay. U138MG cells were transfected with 100 nM of siRNA pool targeted against 
AEBP1 and cultured over a period of 11 days. Caspase activity was measured at different time points by using the 
Caspase-GloTM3/7 assay kit (Promega, WI) according to the manufacturer’s protocol. Briefly, Caspase-Glo 3/7 
solution was added to the culture media and incubated at 37 °C for 30 min in a cell culture incubator. The con-
tents of each well were mixed carefully with a micropipette and 50 µl of this mixture was transferred to a 96-well 
polystyrene assay plate (Corning Inc., NY) and the light emitted was read in a microplate luminometer at 570 nm.
Pan-caspase inhibition and cell viability assay. U138MG cells were plated in 96-well plates and were 
transfected every 36 hours with 100 nM of siRNA pool designed against AEBP1 or non-targeting scrambled 
siRNA as a control for a period of 9 days. HeLa cells were treated with 10 µg/ml doxycycline (Sigma Aldrich) 
for inducing caspase mediated apoptosis. To check the involvement of classical caspase pathway, pan-caspase 
Inhibitor Z-VAD-FMK (Promega) was added at a final concentration of 20 mM, two hours prior to either doxy-
cycline treatment or AEBP1 siRNA treatment. After completion of treatment, cells were treated with MTT (3-[4-5 
dimethyl thaizole-2-yl]2-5 diphenyltetrazolium bromide (Sigma-Aldrich) for 4 hours and the formazan crystals 
formed by metabolically active cells was solubilized in DMSO and measured in a spectrophotometer at 550 nm.
Immunofluorescence assay. Cells were grown on coverslips and subjected to AEBP1 down regulation as 
described above. After desired period of incubation, cells were fixed with 4% paraformaldehyde for 20 minutes, 
permeabilized with 0.1% triton X-100 for 10 minutes and blocked with 1% BSA. Cells were incubated with pri-
mary antibodies in 1X PBS with 1% BSA at 4 °C for overnight. The primary antibodies used were rabbit anti-AIF 
antibody (Abcam), rabbit anti- PI3 Kinase p110 beta antibody (Abcam) and mouse monoclonal anti-γH2AX 
antibody (raised in house). Appropriate secondary antibodies conjugated with Alexa fluor 488, 568, or 633 
(Invitrogen/Molecular Probes) were used. The secondary antibody was added and incubated for one hour at 
room temperature. Mitotracker Red CMXRos dye (Life Technologies) was used to assess the mitochondrial outer 
membrane potential (MOMP).
Immunoprecipitation. Cells were treated with lysis buffer (50 mM Tris pH7.4, 0.1% NP40, 100 mM NaCl, 
0.1 mM EDTA, 1% Glycerol, 1 nM PMSF, 1X Protease Inhibitor Complex and 5 mM MgCl2).The total cell lysate 
was precleared with Protein A agarose beads (Invitrogen) and the lysate was incubated with antibody of interest, 
overnight at 4 °C in an end to end rotator. Preimmune-IgG was used as a negative control. Protein-A-agarose 
beads were added in 1/10th measures of the lysate at 4 °C for 4 hours. Beads were collected and washed with the 
lysis buffer 2–3 times. These samples were prepared to load on a 10–15% SDS-PAGE and were blotted on to a 
membrane and probed.
Chromatin immunoprecipitation (ChIP). Cells were cross-linked with 1% formaldehyde and the reac-
tion was quenched with glycine (0.125 M). They were resuspended in ChIP incubation buffer (0.1% SDS, 0.5% 
Triton X-100, 20mMTris-HCl pH8, and 150 mM NaCl) and sheared using a bioruptor sonicator (Diagenode). 
Sonication efficiency was standardized to get an enrichment of DNA fragments in the range of 600 bp to 2 kb. The 
sonicated chromatin was centrifuged for 15 min and resuspended in IP buffer (20 mM Tris/HCl pH7.4, 150 mM 
NaCl, 2 mM EDTA, 10% glycerol, 1% Triton X-100 and Mammalian Protease Inhibitor Complex) and the result-
ant lysate was precleared using Protein A agarose beads (Invitrogen) and then incubated with 3 μg of histone 
H3 antibody or 3 μg of mouse IgG (negative control) for 12 h at 4 °C. The immune complex was captured with 
Protein A agarose beads for 4 h at 4 °C. The beads were successively washed twice with Buffer 1 (0.1% SDS, 0.1% 
deoxycholate, 1% Triton-X 100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]) and once 
with Buffer 2 (0.1% SDS, 0.1% sodium deoxycholate, 1% Triton-X 100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 
20 mM HEPES [pH 7.6]). The captured chromatin fragments were eluted by incubation of the beads with elution 
buffer (1% SDS, 0.1 M NaHCO3) at room temperature for 20 min. The proteins associated with precipitated chro-
matin was further resolved on 10% SDS PAGE, blotted onto a membrane and probed with AIF and γH2AX anti-
bodies. For ChIP PCR the DNA associated with precipitated chromatin was isolated and analysed using qPCR. 
The primers used in the study are listed in Table S2.
Subcellular fractionation. Cells were trypsinised and washed with PBS and lysed with Buffer 1-Digitonin 
Buffer (150 mM NaCl, 50 mM HEPES, 7.5 µg/ml digitonin +1% mammalian protease inhibitor Complex) in an 
end to end rotator for 10 minutes at 4 °C and centrifuged at 2000 × g. The supernatant was taken to be the cyto-
solic fraction. The resultant pellet was resuspended in Buffer 2-NP40 Buffer (150 mM NaCl, 50 mM HEPES pH 
7.4, 1% NP40), left on ice for half an hour and centrifuged at 7000 × g. The supernatant contained the mem-
brane rich fractions. The pellet was further resuspended in ice cold Buffer 3- RIPA buffer (150 mM NaCl, 50 mM 
HEPES, 0.5% sodium deoxycholate, 0.1% SDS and 1% DNase) and incubated in an end to end rotator for an hour 
at 4 °C after which the suspension was centrifuged at 7000 × g for 10 minutes. The pellet containing insoluble 
proteins was resuspended in the RIPA extraction buffer- Buffer 4 (150 mM NaCl, 50 mM HEPES, 0.5% sodium 
deoxycholate, 1% SDS, 100 mM dithiothreitol), and the resultant suspension was mixed with the supernatant 
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from buffer 3 to obtain the nuclear lysate. The purity of the fractions was confirmed using western blot probing 
with fraction specific protein marker antibodies.
Flow cytometry. Cells were grown in 65 mm dishes and subjected to AEBP1 down regulation up to 9 days, 
as described earlier. Cells were harvested at different time points to analyse the change in Mitochondrial Outer 
Membrane Potential, using the MitoTracker® Red CMXRos (Life Technologies) (100 nM) as per manufacturer’s 
protocol. Briefly, after the treatment cells were trypsinised and centrifuged at 900 × g and washed with PBS. The 
cell pellet was resuspended in PBS. Un-transfected cells without adding the mitotracker dye were used as template 
to adjust the frequency and voltage to mask the autofluorescence. MitoTracker® Red CMXRos dye was added 
to scrambled siRNA and AEBP1 siRNA treated samples. Cells were analyzed using FACS Aria Cell Sorter (BD 
Biosciences) with an emission wavelength of 577 nm.
Analysis of DNA fragmentation. After the AEBP1 siRNA treatment as already mentioned above, cells 
were trypsinised and centrifuged at 900 × g and washed with PBS and fixed for half an hour in 50% methanol at 
4 °C. The solution was diluted in the ratio 1:1 with PBS and the cells were centrifuged down at 900 × g. This was 
followed by RNase treatment (50 µg/ml) for 1–3 hours at 37 °C and incubated with PI for 1 hour at 37 °C. Cells 
were analyzed using FACS Aria Cell Sorter (BD Biosciences) with an emission wavelength range of 580–630 nm.
Intra-nucleosomal DNA ladder formation assay. Cells were collected after AEBP1 siRNA treatment 
and DNA fragments were isolated according to the standard protocol for DNA isolation23. Briefly, glioma cells 
were treated with AEBP1 siRNA, harvested, counted and washed with PBS at 4 °C. The cells were pelleted by cen-
trifugation at 200 g at 4 °C. The pellet was suspended in DNA lysis buffer (1 M Tris, pH 8.0, 0.5 M EDTA and 75% 
sodium lauryl sarcosine) and incubated overnight with proteinase K (0.5 mg/mL) at 50 °C. After overnight incu-
bation, RNase was added and the cells were again incubated for 1 h at 50 °C. DNA was extracted using phenol/
chloroform (1:1 v/v) and then electrophoresed in 2% agarose gel for 2 h at 50 V. The gel was stained with ethidium 
bromide (0.5 μg/mL) and photographed under UV trans-illuminator.
Quantitative real time-PCR measurement of AEBP1 and PI3KCB genes. To assess the gene expres-
sion of AEBP1 and PI3KCB upon siAEBP1, qRT-PCR were performed from total RNA extracted from experi-
mental cells by using Trizol reagent and reverse transcription was carried out with RevertAid first strandcDNA 
synthesis kit (ThermoScientific, USA) according to the manufacturer’s protocol. qRT-PCR was performed in 
BioRad CFX96 Real-Time PCR System by using SensiFAST SYBR® No-ROX Kit (Bioline Reagents Ltd). Each 
qRT-PCR reaction (in 25 μL) involved 12.5 μL 2x SensiFAST SYBR No-ROX Mix, 1 μL of each primer, 2 μL cDNA 
and 8.5 μL H2O. The cycling conditions included an initial single cycle (95 °C for 3 min), and followed by 40 cycles 
(95 °C for 15 s; 57–60 °C for 15 s; 72 °C for 20 s). All amplifications were followed by dissociation curve analysis of 
the amplified products. Specific primers were designed using the NCBI, specificities were confirmed with BLAST 
and gene expression levels were normalized with GAPDH to attain the relative expression by using 2(−ΔΔCt) value 
methods (Supplementary Table S2).
Over expression of PI3KCB and ectopic expression of PTENWt in U138MG cells. The PTEN wild 
type cDNA was amplified from LN18 cells derived cDNA by using sequence specific primers that incorporated 5′ 
HindIII and 3′ BamHI restriction sites (Supplementary Table S2) which was subsequently cloned into the plasmid 
vector pcDNA3.1(+) vector to generate pcDNA-PTENWT. PIK3CB ORF clone from GenScript (OHu21708D) 
was procured to over express PIK3C beta in U138MG cells. Briefly, U138MG cells were transfected with 
pcDNA-PIK3CB or pcDNA-PTENWT construct or pcDNA3.1+ (negative control) by using Lipofectamine 2000 
(Life technologies). Over expression of PIK3C beta and ectopic expression of PTENWT was confirmed by probing 
PIK3Cbeta or PTEN in total protein extracts after 72 of post-transfection with anti-PIK3C beta or anti-PTEN 
antibody.
Statistical analysis. All statistical data were analysed by GraphPad Prism 5 software. Two-tailed Student’s 
t-test and two-way ANOVA tests were used appropriately, and a P < 0.05 was considered statistically significant. 
Unpaired parametric t-tests were used to analyze means of two groups. Bar graphs show the mean ± SD of bio-
logical replicates.
Results
Caspases are not activated under AEBP1 down regulated condition in U138MG cells. In order 
to understand the mechanism of cell death induced upon AEBP1 siRNA mediated down regulation in U138MG 
glioma cells, we initially explored the involvement of classical caspase mediated apoptotic pathway in this pro-
cess24. On probing the initiator caspases, both caspase 8 (extrinsic or ligand mediated pathway) and caspase 9 
(intrinsic or mitochondrial pathway), we observed that neither of these caspases were activated upon AEBP1 
down regulation in U138MG glioma cells (Fig. 1a). In the doxycycline treated HeLa cells which was used as a 
positive control25,26, we observed the activation of caspase 8, 9 and 3. Further, we also probed the mitochondrial 
membrane protein Bid as Bid cleavage has been reported to activate caspase 8 through apoptosome complex27. 
Here also we did not observe any cleaved Bid product in AEBP1 down regulated U138MG cells. Next we inves-
tigated the cleaved caspase 3, which is a common downstream signaling event in the caspase cascade and we did 
not observe cleaved caspase 3 under these conditions (Fig. 1a). These findings were further validated by probing 
for both the executioner caspases, caspase 3 and 7 using caspase glo3/7 assay using doxycycline treated HeLa cells 
as a positive control. While doxycycline activated caspases 3/7 were observed in HeLa cells as seen in Fig. 1b, a 
similar activation was not observed in AEBP1 down regulated U138MG cells. To further substantiate the obser-
vation that caspase pathway is not involved in AEBP1 down regulated cell death of U138MG cells, we carried out 
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cell viability assay of these AEBP1 depleted U138MG cells in the presence and absence of pan caspase inhibitor 
Z-VAD-FMK, which inhibits caspase dependent cell death. For this purpose, AEBP1 was silenced in U138MG 
glioma cells using 100 nM AEBP1 siRNA pool, which was replenished every 36 hours over a period of 9 days and 
assessed for cellular viability MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)assay. MTT 
assay is a colorimetric assay for assessing cell metabolic activity and consequently cell viability and proliferation28. 
NAD(P)H-dependent cellular oxidoreductase enzymes reduce MTT to insoluble, purple formazan crystals which 
was further solubilised in solvent. Absorbance of the solution was quantified by measuring at 500 and 600 nm by 
a spectrophotometer. In parallel, cells were treated with doxycycline, an inducer of caspase mediated cell death. 
Pan-caspase inhibitor was added 12 hours after each treatment and subjected to MTT assay as mentioned above. 
We observed that upon addition of pan caspase inhibitor, doxycycline treated U138MG cells showed no loss in 
cell viability (Fig. 1c), whereas cell death was observed in AEBP1 down regulated U138MG cells (Fig. 1d). All 
these results clearly suggest that classical caspase pathway components are indeed present in U138MG glioma 
cells, but however, the pathway is not activated under AEBP1 depleted conditions. Finally, we probed for the 
cleavage of DNA nick sensing repair enzyme, PARP-1. PARP-1 is cleaved and inactivated by cleaved caspase 3. 
As expected we did not observe any cleaved PARP-1 under the experimental conditions, instead we noted higher 
Figure 1. Caspases are not activated upon cell death induced by AEBP1 down regulation in U138MG cells. 
(a) Western blots of cleaved caspases 8, 9 and 3, cleaved Bid, native PARP-1 and cleaved PARP-1 with GAPDH 
as the loading control. Cells were treated with siAEBP1 upto 11 days and harvested at different time points 
as mentioned. Scrambled siRNA treated U138MG and untreated HeLa cells were used as negative controls 
while doxycycline (10 μg/ml) treated HeLa cells served as a positive control. (b) Caspase Glo Assay, probed for 
Caspase 3/7 in U138MG cells upon AEBP1 down regulation. Negative controls were scrambled siRNA treated 
U138MG and untreated HeLa cells while doxycycline (10 μg/ml) treated HeLa cells served as positive control. 
*p < 0.05, **p < 0.001, ***p < 0.0001 and NS, Non-significant. (Untreated versus Dox treated in HeLa cells 
and Scrambled (ScSi) versus siAEBP1 in U138MG cells). One-way ANOVA followed by Dunnett’s test was used 
to evaluate the statistical significance. The data are expressed as mean ± SD (n = 3). (c) Activation of caspase 
pathway in U138MG cells upon doxycycline treatment using MTT assay. Pan-caspase inhibitors treatment 
shows restoration of cellular viability. (d) AEBP1 down regulation induces cell death in U138MG cells despite 
addition of Pan Caspase inhibitors. Two sets of cells were treated with AEBP1 siRNA while one of them was 
treated with Pan-caspase inhibitors, 2 hours post siRNA treatment. Cellular viability was measured using the 
MTT assay. (e) Densitometry analysis of uncleaved PARP-1 upon down regulation of AEBP1 (Fig. 1a); PARP-1 
is maximally over expressed 5 days post treatment. ***p < 0.0001, scrambled (ScSi) versus siAEBP1 treated 
cells. One-way ANOVA followed by Dunnett’s test was used to evaluate the statistical significance. The data are 
expressed as mean ± SD (n = 3).
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level expression of native PARP-1 in comparison to scrambled siRNA (ScSi) treated U138MG cells (Fig. 1e). 
However, under similar experimental conditions, doxycycline treated HeLa cells did show cleaved PARP-1 
(Fig. 1a).
DNA damage and PARP-1 over activation in AEBP1 depletion condition. Caspase mediated apop-
tosis is characterized by the fragmentation of genomic DNA generating nucleosomal ladder pattern15,24. When we 
analyzed the genomic DNA of AEBP1 silenced U138MG cells, we did not observe any pattern of DNA fragments 
reminiscent of nucleosomal ladder (Fig. 2a; lane 6–9). However, we did observe a smear of genomic DNA approx-
imately around 50 Kb in AEBP1 siRNA transfected U138MG cells indicating that DNA is cleaved randomly to 
generate approximately 50 Kb large sized fragments. However, we observed DNA ladder formation in doxycycline 
treated U138MG cells at 50 ug/ml (Supplementary Fig. 2). We further corroborated this large scale DNA frag-
mentation by FACS analysis of cells after staining with propidium iodide. These results shown in Fig. 2b reveal 
that on 7th day and 9th day post AEBP1 siRNA transfection, most of the cells were in P1 quadrant, representative 
of sub G0/G1 cells having DNA content less than ‘n’, which is indicative of large scale fragmentation of DNA. As 
previously shown, cell proliferation was impeded and viability decreased from 5th day onwards8.
Apoptosis inducing factor (AIF) is a mitochondrial flavoprotein involved in bioenergetics and redox metab-
olism29–31. Loss of mitochondrial outer membrane potential causes leakage of AIF16. AIF then leaches into the 
cytosol and further translocates to the nucleus, where it participates in peripheral chromatin condensation and 
chromatinolysis32,33. This release of AIF from mitochondria is believed to be triggered by PARP-1. The synthesis 
Figure 2. Activated PARP-1 leads to loss of MOMP mediated chromatinolysis. (a) AEBP1 silenced U138MG 
glioma cells (Lanes 6–9) show accumulation of large 50Kb fragments while doxycycline treated HeLa cells 
(Lane 3) show typical nucleosomal ladder pattern characteristic of apoptosis. (b) FACS analysis shows 
accumulation of sub n population of cells in AEBP1 down-regulated U138MG cells. AEBP1 siRNA treated 
cells were labeled with PI (50 µg/ml) and were gated for the Sub G0 population as P1 in a Pulse Area Vs Pulse 
Width of the PE- 561 nm laser. (c) PARP-1 activation was monitored with PAR polymer production by western 
blot analysis at various time points upon AEBP1 down regulation. Un-transfected and scrambled siRNA (ScSi) 
treated U138MG cells were used as controls. (d) FACS analysis of Mitotracker measured at 577 nm in a Count 
Vs. Pulse-Area graph. Cells with live mitochondria metabolize the chloro-methyl moiety converting to a red 
fluorescent dye which can be read at 577 nm. The number in the graph is an average of three independent 
experiments indicating the percentage of cells showing signal at given time point and within the threshold 
intensity.
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of PARP-1 is linked to DNA repair in the nucleus17. Excessive activation of PARP-1 leads to an intrinsic cell death 
program, poly (ADP-ribose) (PAR) polymer (PAR) that is synthesized in the nucleus and released into the cyto-
plasm where it triggers the release of AIF from the mitochondria34,35. Since PARP-1 was not cleaved under AEBP1 
depleted conditions in U138MG cells (Fig. 1a) we probed for PARP-1 activation induced PAR polymer formation. 
PAR polymer was measured in a time dependent manner upon AEBP1 down regulation and it was observed that 
there was an increase in the formation of this polymer on the 3rd day which was increased several fold on the 5th 
day post AEBP1 down regulation (Fig. 2c). However, we did not detect PAR polymer from 7th day onwards. From 
these observations we inferred that AEBP1 down regulation causes caspase independent cell death and this cell 
death is mediated by PARP-1 and this might release the AIF from the mitochondria.
Loss of MOMP and AIF release from the mitochondria. Mitochondria sequester various pro apoptotic 
proteins within its inter-membrane space; consequently, the integrity of the outer mitochondrial membrane is 
essential for a healthy normal cell18,36. The disruption of the outer mitochondrial membrane is essential for initi-
ating cell death. We therefore examined whether there is a loss of outer mitochondrial membrane potential/loss 
of membrane integrity in AEBP1 depleted U138MG cells. To investigate this possibility, we used MitoTracker Red 
CMXRos, a red-fluorescent dye that stains mitochondria in live cells and its accumulation within the mitochon-
dria is dependent on positive membrane potential. The loss of membrane integrity and subsequent mitochon-
drial leakage causes drop in the membrane potential and hence reduction in staining intensity. As can be seen 
in Fig. 2d, we observed that 91.17% of the cells treated with scrambled siRNA showed positive MOMP whereas 
AEBP1 depleted cells showed loss of MOMP as days of treatment progressed. There was a significant decrease 
in Mitotracker staining on 5th day post transfection (70.66%) which showed a further decrease on 7th day post 
AEBP1 siRNA (86.66%) and 9th day (86.94%) post AEBP1 siRNA treatment.
As a consequence of this loss of mitochondrial outer membrane integrity, we expected AIF to be released 
from the mitochondria. The release of AIF was monitored by both immunofluorescence and sub cellular frac-
tionation. As can be seen in Fig. 3a,b, we observe the release of AIF from mitochondria from 5th day onwards. 
AIF tends to accumulate in the peri-nuclear region by the 5th day and ultimately moves into the nucleus on the 
7th day and is predominantly in the nucleus on the 9th Day. This was further validated by western blotting analysis 
of the sub cellular fractions (Fig. 3c). We did not observe any AIF in the nuclear fraction in scrambled siRNA 
treated U138MG glioma cells. Despite molecular association studies on AIF, yet we still do not understand the 
molecular function of AIF inside the nucleus particularly in chromatinolysis15,35. Recently, Wang et al.19 have 
identified macrophage inhibitory factor (MIF) as a PARP-1-dependent AIF associated nuclease that is required 
for parthanatos and also have shown that AIF is required for recruitment of MIF to the nucleus. An earlier study 
has shown that MIF is highly expressed in human glioma cell lines which increases further with the grade of 
malignancy of human glioma patients37. We have observed that MIF is expressed in the four selected glioma cells 
(Supplementary Fig. 3) and in this background, we hypothesized that MIF’s nuclease activity and AIF-mediated 
recruitment are required for AEBP1 down regulation induced parthanatos. To prove this hypothesis, we checked 
for the subcellular localization of MIF in AEBP1 down regulated U138MG cells by western analysis. As shown 
in the Fig. 3d,e, we observed that MIF levels gradually increased in the nuclear fractions of AEBP1 silenced 
U138MG cells from 3rd to 11th day while there was a corresponding decrease in its cytoplasmic level. These obser-
vations confirm that AEBP1 down regulation in U138MG cells leads PARP-1 over-activation resulting in higher 
PAR polymer formation. It is quite likely that PAR polymers which translocate from nucleus to cytoplasm, trigger 
the AIF release from mitochondria by altering the MOMP. In the presence of nuclear translocated AIF, MIF more 
efficiently cleaves the genomic DNA into larger fragments19.
AEBP1 depletion increases γH2AX foci in the nucleus. Since AEBP1 down regulation resulted in 
MIF mediated large scale DNA fragmentation in the nucleus because of AIF translocation, we predicted that it 
is quite likely that double strand breaks may be accumulating under AEBP1 depleted condition. We examined 
the levels of double strand breaks in U138MG cells following AEBP1 down regulation by monitoring γH2AX 
foci through immunofluorescence analysis. Cancer cells by default tend to accumulate double strand breaks38 
which are very low in control un-transfected and scrambled siRNA treated U138MG cells as shown in Fig. 4a. 
However upon AEBP1 down regulation, there is a steady increase in the number of γH2AX foci progressively on 
5th, 7th and 9th day post AEBP1 siRNA transfection (Fig. 4b). It is also interesting to note that the γH2AX foci are 
predominantly in the nuclear periphery to begin with and at later time points, there were many more foci accu-
mulating in the core of the nucleus. We were curious to know whether these γH2AX foci are associated with AIF 
bound chromatin domains in AEBP1 depleted U138MG cells. We isolated chromatin fractions from the 7th day 
post AEBP1 siRNA transfected cells and immunoprecipitated with either AIF or γH2AX antibodies and probed 
for the other protein and the results are shown in Fig. 4c,d. We checked whether MIF also associates with the 
γH2AX-associated chromatin which was demonstrated in Fig. 4e. These results clearly demonstrate that γH2AX 
foci are in the same chromatin domain interacting with AIF-MIF in the nucleus.
Increase in DSB foci is mediated by PI3KCB down regulation. Next, we addressed the possible rea-
sons for the accumulation of DSBs and DNA fragmentation in the absence of AEBP1. The basal levels of PAR are 
very low in cancerous cells17. However, excessive activation of PARP-1 leads to 10–500-fold increase in PAR pol-
ymer formation39. PARP-1 is activated by DNA damage that is inherent to cancer and massive DNA damage may 
lead to rapid activation of PARP-1 and PAR formation. Thus, an obvious question that arises at this point is the 
reason for such a significant increase in PAR polymer formation in AEBP1 depleted U138MG cells. Recently it has 
been shown that PI3Kβ is necessary for the double stranded DNA break sensing40. Inhibition of PI3Kβ has been 
shown to retard the DNA damage repair process21 and cause genomic instability. Previously it has been shown 
that down regulation of PI3KCB leads to loss of cell proliferation, cell cycle arrest and apoptosis21. This function 
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for PI3Kβ is independent of its kinase activity41. The micro array data from our previous work showed a 1.52 fold 
down regulation of PI3KCB upon silencing AEBP18. We have reconfirmed that PI3KCB is indeed down regulated 
under AEBP1 down regulated conditions at mRNA and protein level in glioma cells (Fig. 5a–d). When we started 
looking for possible reasons for PI3KCB down regulation, we observed that the PI3KCB promoter (−2Kb) has 
AEBP1 binding motifs. PI3KCB was also listed as one of the genes with AEBP1 binding motif in our previous 
ChIP-chip analysis8. We further validated this by chromatin immune precipitation with anti-AEBP1 antibody 
and subsequent semi-quantitative and quantitative PCR of the immune precipitated DNA fragments (Fig. 5e; 
Supplementary Fig. 4). Next, we proceeded to demonstrate that AEBP1 does regulate PI3KCB gene regulation by 
carrying out luciferase reporter assay with −2000 to +200 bp of PI3kinase 110 CB cloned into pGL3 vector. For 
this purpose, both U138MG and HeLa cells were transfected with pGL3 construct and other controls along with 
β-galactosidase construct to normalize for transfection efficiency. We observed PIK3CB promoter was indeed 
functional in U138MG cells and the promoter activity was decreased upon AEBP1 down regulation (Fig. 5f–i). 
There was no functional PIK3CB promoter activity in HeLa cells which does not express AEBP1 (Supplementary 
Fig. 5). Hence, it is very likely that down regulation of PI3KCB is most likely the reason for accumulation of DSB 
foci observed in our experiments. To identify the positive correlation between AEBP1 and PIK3CB in in vivo, 
we downloaded the GBM TCGA dataset42 from cBioportal43 and extracted median expression values of AEBP1 
and PIK3CB from PTEN homozygously deleted (n = 12) and non-altered PTEN (n = 154) samples. Correlation 
between the AEBP1 and PIK3CB was computed using cor.test function in R software and plotted scatter plot 
using ggplot2 R package. As shown in the Fig. 5j, there was strong positive correlation between AEBP1 and 
PIK3CB in GBM cases compared to normal tissues. To further substantiate our hypothesis that down regulation 
of PI3KCB is a causative event for DSB accumulation in AEBP1 down regulated cells, we carried out a time course 
Figure 3. AEBP1 down regulation releases AIF from mitochondria which translocates to the nucleus along 
with MIF. (a) Triple Immunofluorescence images of U138MG cells representing AIF and mitotracker together 
with DAPI showing movement of AIF from mitochondria to nucleus and loss of MOMP upon AEBP1 silencing 
in U138MG cells. (Scale Bar-10 μm). (b) Graphical representation of percentage of cells showing AIF nuclear 
localization upon AEBP1 silencing up to 9 days. Cells were counted manually for each day post transfection 
with siAEBP1. ***p < 0.0001 and NS, Non-significant. (Scrambled (ScSi) versus siAEBP1 treated cells). One-
way ANOVA followed by Dunnett’s test was used to evaluate the statistical significance. The data are expressed 
as mean ± SD (n = 3). (c) Subcellular localization of AIF. Upon AEBP1 silencing, cells were subjected to sub 
cellular fractionation yielding cytoplasm, nuclear extract and membrane rich fractions. Western blotting of 
different fractions shows AIF retention in membrane rich fractions up to 5th day post siAEBP1 transfection. 
AIF intensity shows an increase in the nuclear fraction on 7th day post siAEBP1 transfection. Histone H3 and 
GAPDH were used as nuclear and cytoplasmic fractions marker respectively. (d,e) Subcellular localization 
of MIF and AIF in U138MG cells upon AEBP1 silencing. Histone H3 and GAPDH are used as nuclear and 
cytoplasmic marker.
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dependent measurement of PI3Kβ disappearance and appearance of γH2AX foci after AEBP1 down regulation 
by immunofluorescence. As can be seen in Fig. 6a, upon AEBP1 down regulation PI3Kβ moves to the nucleus and 
PI3K foci can be observed at 3 days post transfection which subsequently decreases significantly on 5th, 7th and 
9th days. Conversely, γH2AX foci continuously increase from 3rd day to 9th day post transfection. We validated 
these results by over expressing PI3KCB in U138MG cells (Supplementary Fig. 6) and visualized the γH2AX foci 
accumulation upon silencing AEBP1. As expected γH2AX foci accumulation was abrogated by PIK3CB over 
expression (Fig. 6b) when compared to pcDNA3.1-vector alone treated U138MG cells (Supplementary Fig. 7). 
Thus, there is a reciprocal relationship between down regulation of PI3KCB and the increase in γH2AX foci in 
AEBP1 depleted cells.
AEBP1 down regulation induces caspase dependent cell death in PTEN-proficient glioma cells. 
It is well-known that genetic alterations of tumor suppressor genes could play an essential role in the pathogenesis 
of glioma. It has been reported that mutation in PTEN are most frequently found in GBM and has been impli-
cated in the pathogenesis of high-grade glioma44,45. Furthermore, PTEN mutations were detected in more than 
70% of glioma cell lines, and the frequencies of these mutations were significantly higher in cell lines than the 
glioblastoma tumors46. To verify the PTEN status of glioma cells, we probed for PTEN with anti-PTEN antibody 
in U87MG, U138MG, LN18 and LN229 cells. As shown in the Fig. 7a, PTEN-deficient cells such as U87MG and 
U138MG cells express mutant PTEN (42KDa) whereas PTEN-proficient cells express wild-type PTEN (55KDa). 
We also verified this by sequencing the cDNA of U87MG, U138MG, LN18 and LN229 cell lines with two pairs of 
PTEN wild-type sequence-specific primers (Supplementary Table 2) and found that U87MG and U138MG cells 
possess two different missense mutations in PTEN exon sequences while there were no mutations in PTEN exon 
sequences of LN18 and LN229 cells (Supplementary Table 1).
Figure 4. AIF translocation into nucleus results in γH2AX foci accumulation. (a,b) Immunofluorescence 
images showing progressive increase in γH2AX foci upon increasing days of AEBP1 down regulation. 
Fluorescence intensity was quantitated and represented in panel b. (Scale Bar-10 μm) ***p < 0.0001 and NS, 
Non-significant. (Scrambled (ScSi) versus siAEBP1 treated cells). One-way ANOVA followed by Dunnett’s test 
was used to evaluate the statistical differences. The data are expressed as mean ± SD (n = 3). (c) AIF-associates 
with γH2AX: Chromatin fraction was isolated from U138MG cells 7 days post siAEBP1 transfection. γH2AX 
was immunoprecipitated using Protein A agarose beads and the eluate from the matrix was probed with 
anti-AIF and anti-γH2AX antibodies. (d) γH2AX associates with AIF: Chromatin fraction was isolated from 
the U138MG cells 7 days post siAEBP1 transfection. AIF was immunoprecipitated using Protein A agarose 
beads and the eluate from the matrix was probed with AIF and γH2AX antibodies. (e) γH2AX associates with 
MIF: Chromatin fraction was isolated from U138MG cells 7 days post siAEBP1 transfection. γH2AX was 
immunoprecipitated using Protein A agarose beads and the eluate from the matrix was probed with anti-AIF, 
anti-γH2AX and anti-MIF antibodies.
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An earlier study has revealed that AEBP1 negatively regulates adipose tissue PTEN levels, in conjunction with 
its role in proliferation and differentiation of pre-adipocytes47. PTEN also acts as a critical determinant of cell 
fate, regarding senescence and apoptosis in glioma cells under ionization radiation exposure48. We were curious 
to examine whether the process of cell death observed in PTEN deficient glioma cells (U138MG and U87MG) 
also occurs in PTEN proficient glioma cells (LN18 and LN229) upon AEBP1 down regulation. We performed 
AEBP1 silencing in LN18 and LN229 cells and observed maximum down regulation at 72 hrs of post-transfection 
for LN18 and LN229 cells respectively (Supplementary Fig. 8a,b). Thus, siRNA pool was replenished every 
60 hours in LN18 and LN229 cells for over a period of 11 days and assessed for cellular proliferation by the MTT 
assay. As shown in Supplementary Fig. 1c, there was no aberrant change in the cell viability until the 3rd day of 
post-transfection. Nevertheless, there was a significant reduction in the cell viability from 5th day onwards sug-
gesting that silencing of AEBP1 resulted in cell death in PTEN-proficient cells also. Interestingly, the activation 
of caspase 3, loss of MOMP and cleavage of PARP-1 was observed after 5 days of post-transfection in LN18 cells 
upon AEBP1 down regulation (Fig. 7b) in contrast to PTEN-deficient U138MG and U87MG cells. Together, these 
data show that AEBP1 down regulation induces caspase-dependent cell death in PTEN-proficient glioma cells.
Figure 5. AEBP1 positively regulates PI3KCB. (a,b) qRT-PCR for PI3KCB expression in ScSi control and 
siAEBP1 treated U138MG (a) and LN18 (b) cells. *p < 0.05 and ***p < 0.0001. (Scrambled (ScSi) versus 
siAEBP1 treated cells). One-way ANOVA followed by Dunnett’s test was used to evaluate the statistical 
differences. The data are expressed as mean ± SD (n = 3). (c,d) Western blot analysis of PI3KCB upon AEBP1 
down regulation in U138MG (c) and LN18 (d) cells. The 5th day lane shows decrease in PI3KCB signal which is 
completely absent in post 7th day of siAEBP1 transfected cells. ScSi treated cells was used as a negative control. 
(e) ChIP-PCR of PI3KCB promoter sequence (−2Kb) showing AEBP1 interaction with the PI3KCB promoter 
in U138MG cells. DMTF, SIVA-1 and ERBB2 gene promoter loci were used as negative controls. (f–i) Luciferase 
reporter assay driven by PI3KCB promoter in U138MG cells upon silencing of AEBP1 for different time periods 
of time. Cells were transfected with constructs of pGL3-Luciferase Basic vector containing one of the following: 
CMV promoter, promoter region of the gene FABP4 (transcriptionally repressed by AEBP1), and PI3KCB 
promoter region. Luciferase assay was performed at different time points after siAEBP1 treatment. *p < 0.05 
and ***p < 0.0001. (Scrambled (ScSi) versus siAEBP1 treated cells). One-way ANOVA followed by Dunnett’s 
test was used to evaluate the statistical significance. The data are expressed as mean ± SD (n = 3). (j) Correlation 
between AEBP1 and PIK3CB expression levels in GBM patients in relation to normal brain tissues retrieved 
from TCGA database through cBioPortal (http://www.cbioportal.org/). White dots refer to individual GBM 
patients. r - Pearson correlation coefficient and p – statistical significance.
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Ectopic expression of wild type PTEN in U138MG cells induces the caspase and Akt dependent cell 
death pathway upon AEBP1 down regulation. From these results described above, we conclude that PTEN 
status in glioma determines the cell fate either through caspase-dependent or independent cell death pathway. Thus, 
we  were curious to know what happens if we provide wild type PTEN (PTENWT) in trans to PTEN-deficient cells. We 
transfected the pcDNA-PTENWT constructs into U138MG and U87MG cells and scored for caspase 3 and PARP-1 
activation after silencing AEBP1. PTENWT expression was observed after 72 hrs of post-transfection when compared 
to pcDNA 3.1+ construct alone transfected cells (Fig. 7c). We observed cleaved caspase 3 and PARP-1 after the 3rd day 
in U87MG cells and 5th day in U138MG cells of AEBP1 post silencing and increased subsequently on 7th and 9th day 
on both cells (Fig. 7d,e). These results indicate that PTEN-deficient cells choose caspase dependent cell death when 
PTEN is provided in trans. We also found that nucleosomal ladder formation in pcDNA-PTENWT-U138MG cells upon 
AEBP1 down regulation (Fig. 7f). This trend was corroborated with PTEN-proficient cells LN18 on 5th day of post 
AEBP1 down regulation (Fig. 7b). These results show that AEBP1 depletion induces caspase-dependent and PARP-1 
mediated cell death in the presence of PTENWT in the PTEN-deficient cells.
It is well-known that Phosphatidylinositol-3-kinase (PI3K) pathway, a downstream target pathway plays 
an essential role in regulating cell death and cell cycle arrest49,50. PTEN induces apoptosis and cell cycle arrest 
through PI3K/Akt dependent and independent pathways in breast cancer cells51. Importantly, correction of 
PTEN mutations in glioblastoma cell lines through gene editing resulted in reduced cell proliferation which was 
Akt-dependent in 42MGBA cells and Akt-independent in T98G cells52. To assess the effect of ectopic expression 
of PTENWT in U138MG cells we performed western blots on protein lysates using Akt specific and pAkt specific 
antibodies. We observed that expression level of Akt was unaltered in all conditions but there was a signifi-
cant decrease in pAkt levels from the 3rd day of AEBP1 silencing under PTENWT ectopic expression conditions 
(Fig. 7g,h; Supplementary Fig. 9). We also validated this trend in PTEN-proficient cells LN18 and LN229 upon 
down regulation of AEBP1 (Supplementary Fig. 10). These results show that ectopic expression of PTENWT in 
U138MG cells induces the Akt dependent cell death pathway in AEBP1 depleted cells. Having these results, we 
were interested to see the correlation between AEBP1 and PIK3CB expression in GBM patients under PTEN 
mutated conditions. We again screened the GBM-TCGA datasets and extracted the data from PTEN deleted 
GBM tissue samples. As shown in the Supplementary Fig. 11 there is no significant correlation between AEBP1 
and PI3Kbeta expression in PTEN deleted GBM cases. This shows that PI3Kbeta expression in clinical GBM 
tumor tissues was independent of PTEN status. Overall, these results show that PTEN status determines the 
choice of cell death pathway in AEBP1 depleted glioma cells.
Figure 6. Ectopic expression of PIK3CB impedes the γH2AX foci accumulation in AEBP1 depleted U138MG 
cells. (a) Triple Immunofluorescence images of AEBP1 down regulated cells at different time points showing 
an increase in γH2AX foci showing translocation of PI3Kβ to the nucleus 3days post siAEBP1 transfection. At 
both time points, PI3Kβ is progressively down regulated. (Scale Bar −10 μm). (b) Overexpression of PIK3CB 
in trans abrogates accumulation of γH2AX foci in AEBP1 down regulated cells: Immunofluorescence images 
showing decreased γH2AX foci accumulation upon AEBP1 downregulation under the condition of PI3KCB 
overexpression. U138MG cells were transfected with pcDNA-PIK3CB ORF clone construct and treated with 
ScSi and siAEBP1 RNA for different time points. (Scale Bar −10 μm).
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Discussion
Despite the enormous progress in our knowledge on the molecular and genetic basis of glioma, little progress has 
been made on molecular de-regulation of cell death pathways in glioma53. Glioblastoma multiforme (GBM) is the 
most malignant tumor of the brain, associated with one of the worst survival rates among all human cancers54. 
Even after aggressive multimodal treatment of surgical resection, local radiotherapy, and systemic chemotherapy, 
the median survival after diagnosis is still around 12–15 months55. After the advent of next-generation sequenc-
ing technology, it is clear that glioblastoma exhibits aberrant metabolic reprogramming56 and striking cellular and 
molecular heterogeneity9 which prevents the effectiveness of the new clinical practice.
In an effort to identify glioblastoma specific diagnostic and prognostic markers through microarray analysis, 
AEBP1 was found up-regulated to greater than 4-fold in primary glioblastoma1. AEBP1 is a member of the car-
boxypeptidase family and is shown to regulate adipogenesis acting as a transcriptional repressor2. Transcription 
factors play a crucial role in the regulation of cellular survival, unrestrained growth and metastatic behavior of all 
Figure 7. Ectopic expression of PTENWT (PTEN-wild type) in AEBP1 depleted U138MG and U87MG 
cells restores the caspase dependent cell death pathway. (a) Western blot analysis of wild type and mutant 
PTEN protein expression in different GBM cell lines. (b) Levels of PARP-1, cleaved PARP-1, cleaved caspase 
3 upon AEBP1 silencing in LN18 cells at different time points. GAPDH was used as a loading control in 
all the experiments. (c) Western blot analysis of ectopic expression of PTENWT in U138MG and U87MG 
cells. U138MG and U87MG cells were transfected with pcDNA 3.1+ (VA) or pcDNA-PTENWT (PTENWT) 
constructs. Total protein was extracted after 72 hrs of post transfection and probed for PTEN. (d,e) Levels of 
PARP-1, cleaved PARP-1, cleaved caspase 3 upon AEBP1 silencing in U138MG (d) and U87MG (e) cells after 
PTENWT transfection at different time points. GAPDH was used as a loading control in all the experiments. (f) 
Accumulation of large scale DNA fragments was observed in U138MG-ScSi and U138MG-PTENWT-ScSi cells 
on 7th day of post siAEBP1 transfection (lane 3 and 4). Ectopic expression of pcDNA-PTENWT in U138MG cells 
induces DNA ladder formation upon AEBP1 silencing on 5th and 7th day of post transfection (lane 5 and 6). 
AEBP1 silencing in LN18 cells shows DNA ladder formation on 5th day of post transfection (lane 7) compared 
to ScSi treated cells (lane 8). (g) Western blot analysis for Akt and phospho-Akt (pAkt) upon AEBP1 down 
regulation in pcDNA-PTENWT cells. (h) Densitometric analysis of Akt and pAkt in AEBP1 depleted cells 
transfected with pcDNA-PTENWT construct. One-way ANOVA followed by Dunnett’s test was used to evaluate 
the statistical differences. ***p < 0.0001 and NS, Non-significant. (Scrambled (ScSi) versus siAEBP1 treated 
cells). The data are expressed as mean ± SD (n = 3).
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human cancer. In our earlier report, we showed that AEBP1 down regulation results in cell death in both U87MG 
and U138MG glioma cells8. We observed perturbation of several apoptotic and growth associated genes under 
AEBP1 down regulation. With this background, we were interested to identify the detailed molecular mechanism 
of cell death in glioma cells under AEBP1 depleted conditions.
In this study, we have shown the role of AEBP1 in initiating caspase-independent cell death in U138MG 
cells. We observed the disruption of the MOMP and the release of AIF into the cytosol and its subsequent 
translocation into the nucleus upon silencing AEBP1. One of the immediate effects of AIF translocation into 
the nucleus is peripheral chromatin condensation57. AIF as a mitochondrial oxidoreductase that mediates the 
caspase-independent cell death12,58. AIF is believed to bind directly to DNA31 and the crystal structure of human 
AIF has revealed the presence of a strong positive electrostatic potential at the AIF surface, and this electrostatic 
interaction between AIF and DNA is independent of the DNA sequence59. The mechanism by which AIF triggers 
DNA fragmentation is still not clear. In Caenorhabditis elegans, WAH1, a homolog of AIF, associates with CPS-6, 
the homolog of mammalian endonuclease G. This association enhances the nuclease activity of CPS-6 and results 
in apoptotic DNA degradation13. It is quite probable that AIF and cyclophilin A collaborate in chromatinolysis35. 
The mechanism of loss of MOMP following AEBP1 down regulation resulting in the release of AIF involves the 
death effector molecule PARP-1. It is an abundant nuclear protein that acts as a molecular sensor of DNA strand 
breaks and mediates its repair32. Thus, the extent of activation of PARP-1 might be a critical factor that regulates 
whether cells either die or survive following DNA damage. We observed that a rapid and substantial PAR polymer 
formation takes place by 5th day post transfection of AEBP1 siRNA. Depending on the stimuli, PAR formed can 
vary in length and in the frequency of branching. This structural heterogeneity by PAR may be in part responsible 
for distinguishing between the life and death functions of PARP-117. PAR polymer formed is highly charged in 
nature and it could conceivably depolarize mitochondria leading to permeability transition and subsequent AIF 
release. Alternatively, PAR polymer could bind to PAR polymer binding proteins in mitochondria17,18, which 
then triggers AIF release from the mitochondria. At the molecular level PARP-1 activation leads to the accu-
mulation of PAR and the depletion of NAD+ and ATP which might disrupt the MOMP60. A very recent study 
has shown that this bioenergetics collapse might not involve NAD but may be due to PAR-dependent inhibition 
of glycolysis through a direct inhibition of hexokinase activity61. Thus, PAR seems to be a crucial molecule in 
caspase-independent AIF mediated cell death. Subsequent release of AIF is a two-step process involving cleavage 
of AIF to be released from the inner membrane and then through the outer mitochondrial membrane by disrup-
tion of MOMP31. Interestingly, an earlier study has shown that AIF interacts with MIF and recruits MIF to the 
nucleus and induces chromatinolysis19. Furthermore, MIF was upregulated in gastric cancer, pancreatic cancer, 
melanoma, hepatocellular carcinoma, malignant glioma and cervical adenocarcinoma62. It plays an important 
pathogenetic role in malignant progression of GBM and other CNS tumours63,64. In particular, a substantial 
increase of MIF expression in human GBM has been reported65,66. We also observed that MIF was recruited into 
nucleus along with AIF upon AEBP1 silencing in U138MG cells. Importantly, MIF was identified as a PARP-
1-dependent AIF-associated nuclease that is required for parthanatos19.
In our previous study we observed enrichment of genes pertaining to activation of PI3Kinase signaling upon 
AEBP1 down regulation in U87MG and U138MG cells8. The present study has also shown that the process of 
cell death initiation in U138MG glioma cells under AEBP1 depleted condition is possibly mediated through 
the transcriptional control of PI3KCB. We have demonstrated that AEBP1 binds to the promoter of PI3kinase 
β resulting in the activation of its transcription. PI3Kinases are a family of enzymes that act downstream of cell 
surface receptors leading to activation of multiple signaling pathways regulating cellular growth, proliferation, 
motility, and survival67. Disruption of normal PI3K signaling is observed in cancer and many other diseases22. 
Out of the many isoforms of PI3K, PIK3CB from class 1A, also called p110β, has been implicated in tumori-
genesis of PTEN-null mouse models and cell lines21,41. In human, mutant p110α is oncogenic, whereas p110-β 
wild-type form is oncogenic68. PIK3CB down-regulation results in cell death pathway inactivation and inhibition 
of growth in both cell-based assays and in vivo animal models. This vital function of PIK3CB in PTEN-deficient 
cancer cells requires its lipid kinase activity suggesting that PTEN-deficient tumors are dependent on p110β sig-
naling69. PTEN is one of the most frequently mutated tumor suppressor gene in glioma compared to other genes 
such as p53, p16 and p14ARF46. A complete loss of PTEN has been observed in glioblastoma and endometrial 
cancer, and PTEN mutations are also associated with advanced cancers and metastases70. This may be as a result 
of the accumulation of PIP3 which promotes the recruitment of the serine/threonine kinase Akt. Akt activation 
promotes cell survival, proliferation, growth, angiogenesis, and therefore is an important survival signal70. Also, 
PTEN-deficient cells enter senescence following ionization radiation (IR) exposure due to its active Akt signaling 
whereas PTEN-proficient cells undergo apoptosis upon IR exposure48. It is well known that AEBP1 interacts with 
PTEN and modulates the adiposity and progression of Alzheimer’s disease47,71. Independent of well-established 
Akt kinase activity in cell survival, PI3Kβ is also necessary for sensing double-stranded DNA breaks, as it regulates 
binding of the Nbs1 sensor protein to Double Strand Breaks (DSBs). In PI3Kβ-deficient cells, the sensing complex 
MRE-11-Nbs-1 complex fails to recognize DSBs resulting in general defects of ATM and ATR repair pathway and 
genomic instability61. In the present study, we have shown that upon AEBP1 down regulation in PTEN-deficient 
cells there is a decrease in PI3Kβ which in return can influence ATM and ATR repair pathway and DNA damage. 
Cancer cells inherently have compromised genomic integrity38. Thus, the down regulation of PI3KCB under the 
AEBP1 silenced conditions results in an accumulation of DSBs as demonstrated by γH2AX foci.
The results presented here also show that AEBP1 down regulation in PTEN-proficient cells (LN18 and 
LN229 cells) activates caspase-dependent cell death pathway in contrast to caspase independent pathway in 
PTEN-deficient cells. Previous studies have shown that PTEN gene transfer in glioma cells72 or correction of PTEN 
gene via genome editing52 suppressed the growth of glioma cells. Most interestingly, ectopic expression of wild type 
PTEN in both U87MG and U138MG cells induced caspase and Akt dependent cell death mechanism. Thus, PTEN 
acts as an essential determinant of the process of cell death switch between chromatinolysis and apoptosis in the 
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glioma cell lines U87MG, U138MG, LN18 and LN229 cells. There is evidence that AEBP1 and PTEN interact in 
the context of adipogenesis and Alzheimer disease47,71. It is quite likely that such an interaction might also occur in 
GBM tumor cells. However, it cannot be ascertained at present how such an interaction might influence the choice 
of cell death pathway between classical caspase dependent apoptosis and parthanatos. The fact that AEBP1 is nec-
essary for cellular viability in both PTEN-proficient and PTEN-deficient tumor cells, suggests that AEBP1 can be 
a good potential target for therapeutic intervention in glioma patients in general irrespective of the PTEN status. 
Therapeutic applications of small molecules targeted at transcription factors are increasingly gaining importance, 
and it is expected that these approaches may revolutionize the anticancer drug options in the near future.
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